A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002044
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: February 1995

November 2, 1999
June 23, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002044 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases
A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases

The purpose of this pilot study is to evaluate the efficacy of Retrovir (AZT) in the treatment of AIDS-related dementia and various neuromuscular complications. HIV is both a lymphotropic and neurotropic virus which can affect both the central and peripheral nervous systems (CNS, PNS). There is evidence that the CNS and PNS may harbor the virus in a latent state, with the potential for continuous reinfection of other body systems. Therefore, effective therapeutic efforts against HIV infection should provide effective antiviral activity within the nervous system.

Not Provided
Interventional
Not Provided
Primary Purpose: Treatment
  • AIDS Dementia Complex
  • Neuromuscular Diseases
  • HIV Infections
Drug: Zidovudine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Past or present renal disease.
  • Significant bone marrow suppression.
  • Blood transfusion within the past month.
  • Liver dysfunction.
  • Evidence of an underlying, severe infection.
  • Evidence of an active life-threatening opportunistic infection at study entry.
  • Severe malabsorption (patients with recent significant weight loss must have a serum carotene level of > 75 IU/ml).
  • Evidence of nervous system dysfunction being caused by factors other than HIV infection, particularly by cerebral toxoplasmosis, lymphoma, cryptococcal meningitis, chronic alcohol abuse, lead poisoning, cytomegalovirus (CMV) infection (patients with retinal CMV infection or other evidence of CMV dementia), syphilis, or progressive multifocal leukoencephalopathy.
  • Other known causes of nerve or muscle disease.
  • Hypersensitivity to zidovudine (AZT).
  • Lymphoma or other tumor requiring cytotoxic chemotherapy.

Concurrent Treatment:

Allowed:

  • Electron beam therapy to an area of less than 100 cm2.

Patients with the following are excluded:

  • Past or present renal disease.
  • Significant bone marrow suppression.
  • Blood transfusion within the past month.
  • Liver dysfunction.
  • Evidence of an underlying, severe infection.
  • Evidence of an active life-threatening opportunistic infection at study entry.
  • Severe malabsorption (patients with recent significant weight loss must have a serum carotene level of > 75 IU/ml).
  • Evidence of nervous system dysfunction being caused by factors other than HIV infection, particularly by cerebral toxoplasmosis, lymphoma, cryptococcal meningitis, chronic alcohol abuse, lead poisoning, cytomegalovirus (CMV) infection (patients with retinal CMV infection or other evidence of CMV dementia), syphilis, or progressive multifocal leukoencephalopathy.
  • Other known causes of nerve or muscle disease.
  • Hypersensitivity to zidovudine (AZT).
  • Lymphoma or other tumor requiring cytotoxic chemotherapy.

Patients with AIDS (CDC surveillance definition) or AIDS related complex (ARC).

  • All patients must have either:
  • Dementia as defined by a progressive cognitive impairment in the absence of altered consciousness that is thought to be causally related to HIV infection. Patients in this study will fall into the lower 20 percent (or less) of a normal sample of formal neuropsychological testing.
  • OR
  • One of the following neuromuscular diseases thought to be related to HIV infection:
  • Demyelinating polyneuropathy, axonal polyneuropathy, inflammatory myopathy, or unexplained progressive muscle weakness.
  • Capacity to give informed consent or a person with durable power of attorney who can give informed consent.
  • Life expectancy = or > 4 months.

Exclusion Criteria

Concurrent Medication:

Excluded:

  • Cytotoxic chemotherapy.
  • Steroids.
  • Interferon.
  • Immunomodulating agents.

Concurrent Treatment:

Excluded:

  • Radiation therapy (except electron beam therapy to an area of less than 100 cm2).

Prior Medication:

Excluded within 4 weeks of study entry:

  • Cytotoxic chemotherapy.
  • Any retroviral drug including but not limited to zidovudine (AZT), ribavirin, HPA 23, AL721, or phosphonoformate.
  • Steroids.
  • Interferon.
  • Immunomodulating agents.
  • An anticipated need for any of these agents within the next 16 weeks.

Prior Treatment:

Excluded within 1 month of study entry:

  • Radiation therapy (except electron beam therapy to an area of less than 100 cm2).
  • Blood transfusion.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002044
014D, 14
Not Provided
Not Provided
Glaxo Wellcome
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
February 1995

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP